Day: September 16, 2022

HAYWARD, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) — Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced it closed its previously announced underwritten public offering of 29,809,471 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase up to 29,809,471 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) was sold together with one common warrant to purchase one share of common stock at a combined offering price of $0.60. The warrants will be exercisable commencing on the effective date of an increase...

New role optimizes resources in cultivation, production and supply chain for maximum output TORONTO, Sept. 16, 2022 (GLOBE NEWSWIRE) — Entourage Health Corp. (TSX-V:ENTG) (OTCQX:ETRGF) (FSE:4WE) (“Entourage” or the “Company”), a Canadian producer and distributor of award-winning cannabis products is pleased to announce the appointment of James Afara as the Company’s Chief Operating Officer (COO). A results-driven leader with an exceptional track record, James brings over 15 years of operations and supply chain experience to Entourage, serving most recently as its Senior Vice President of Strategic Sourcing, Quality Assurance and Cultivation. His promotion comes at a pivotal time as the Company integrates all functional teams in cultivation, tissue culture, production, operations and supply chain under one leader, to align core...

Positive interim clinical data further validate the modularity of Intellia’s industry-leading genome editing platform and its potential to target a multitude of genetic diseases A single dose of NTLA-2002 led to a 65% and 92% mean plasma kallikrein reduction at 25 mg and 75 mg doses, respectively, at week eight HAE attacks were reduced by 91% in the 25 mg dose cohort through week 16; two of three patients remain attack free since treatment with third patient attack free since week 10 through latest follow-up NTLA-2002 was generally well-tolerated at both dose levels Intellia plans to initiate the Phase 2 dose-expansion portion of the study in 1H 2023 Intellia to host investor event today, Friday, September 16, at 8:00 a.m. ETCAMBRIDGE, Mass., Sept. 16, 2022 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading...

UAB “Atsinaujinančios Energetikos Investicijos” (the Company), legal entity code: 304213372, registered at: Jogailos str. 4, 01116, Vilnius, the Republic of Lithuania. The total nominal value of the issued notes of the Company: EUR 40,000,000; ISIN code: LT0000405938. The Company informs that, in accordance with the requirements of Transparency Directive 2004/109/EC, The Republic of Lithuania is its Home Member State. Contact person for further information: Tomas Milašauskas Manager of the Investment Company tomas.milasauskas@lordslb.lt www.lordslb.lt/AEI_green_bonds

Interim data from the cardiomyopathy arm of the Phase 1 study of NTLA-2001 showed deep and sustained mean serum transthyretin (TTR) reductions of 93% and 92% at 0.7 mg/kg and 1.0 mg/kg doses, respectively, at day 28 NTLA-2001 was generally well-tolerated at both dose levels Intellia to discuss data at investor event today, Friday, September 16, at 8:00 a.m. ETCAMBRIDGE, Mass. and TARRYTOWN, N.Y., Sept. 16, 2022 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced positive interim results from an ongoing Phase 1 clinical trial of NTLA-2001, an investigational, in vivo CRISPR/Cas9 genome editing therapy in development as a single-dose treatment for transthyretin (ATTR) amyloidosis. The interim data include 12 adult patients with ATTR amyloidosis with cardiomyopathy...

CLEARFIELD, Pa., Sept. 16, 2022 (GLOBE NEWSWIRE) — CNB Financial Corporation (“CNB”) (NASDAQ: CCNE), the parent company of CNB Bank, announced today the pricing of its underwritten public offering of 3,702,127 shares of its common stock at a public offering price of $23.50 per share, resulting in gross proceeds of approximately $87 million. The net proceeds to CNB after deducting the underwriting discount and estimated offering expenses are expected to be approximately $81.7 million. CNB intends to use the net proceeds from the offering for general corporate purposes, which may include working capital and the funding of organic growth or potential acquisitions. In addition, CNB has granted the underwriters a 30-day option to purchase an aggregate of up to an additional 555,319 shares of common stock. PNC FIG Advisory, part of PNC...

Millicom (Tigo) and Glasswing International launch joint mentorship program to support students and young professionals in Latin America Glasswing honors Millicom (Tigo) and presents CEO Mauricio Ramos with recognition at New York GalaLUXEMBOURG, September 16, 2022 – Millicom (Tigo) and Glasswing International announced the launch of a joint mentorship program to support students and young professionals in Latin America last night at Glasswing’s Eighth Annual Benefit Gala in New York City. Glasswing, a non-profit organization that empowers individuals and communities, also honored Millicom (Tigo) for building digital highways that connect people, improve lives, and develop communities at the event, which celebrated Glasswing’s 15-year anniversary. The mentorship program will initially focus on supporting the Central American Service...

SUGAR LAND, Texas, Sept. 16, 2022 (GLOBE NEWSWIRE) — Applied Optoelectronics, Inc. (Nasdaq: AAOI), a leading provider of fiber-optic access network products for the internet datacenter, cable television (CATV) broadband, telecom and fiber-to-the-home (FTTH) markets, today launched a new family of HFC products under its Quantum BandwidthTM brand name. The newly announced Quantum BandwidthTM products include:Quantum BandwidthTM Cable Plant Signal Generator (CPSG). Capable of generating OFDM and 256-QAM signals from 54 MHz to 1794 MHz. Used in testing and performance validation of Extended Spectrum DOCSIS HFC equipment, the CPSG is able to generate signals necessary to test a cable TV network under full channel loading. Quantum BandwidthTM Broadband Digital Access (BDA) shelf module. The shelf is intended to be used in a HFC headend...

LAFAYETTE, Ind., Sept. 16, 2022 (GLOBE NEWSWIRE) — Wabash (NYSE:WNC), the innovation leader of connected solutions for the transportation, logistics and distribution industries, today announced it will participate in the D.A. Davidson Diversified Industrials and Services Conference on September 22, 2022, in Nashville, TN. President and Chief Executive Officer Brent Yeagy will participate in a panel discussion at 11:00 a.m. CT, where he is expected to discuss Wabash’s refreshed strategy and growth initiatives that drive toward the company’s previously announced 2025 financial targets of $3.0B in revenue, 11% EBITDA margin and $3.50 EPS. Wabash: Changing How the World Reaches YouAs the innovation leader of connected solutions for the transportation, logistics and distribution industries, Wabash (NYSE: WNC) is Changing How the World...